| ¿µ¹® | hyperbaric oxygenation therapy | ÇÑ±Û | °í¾Ð»ê¼Ò¿ä¹ý |
|---|---|---|---|
| ¼³¸í | ´ë±â¾Ðº¸´Ù ³ôÀº ±â¾Ðȯ°æÀ» ÀΰøÀûÀ¸·Î ¸¸µé¾î ±× ¾È¿¡¼ °í³óµµÀÇ »ê¼Ò¸¦ ÈíÀÔ½ÃŰ´Â ¿ä¹ý. Çѱ¹¿¡¼ ¿¬Åº°¡½º·Î ´ëÇ¥µÇ´Â ÀÏ»êÈź¼ÒÀÇ ±Þ¼ºÁßµ¶ÀÇ Ä¡·á¿¡ ¸¹ÀÌ ÀÌ¿ëµÈ °ÍÀ¸·Î, º¸Åë 3´ë±â¾Ð Á¤µµ·Î °¡¾ÐµÈ °í¾Ð»ê¼Ò½ÇÀ̳ª °í¾Ð»ê¼ÒÅÊÅ© ¼Ó¿¡ ȯÀÚ¸¦ ³õ°í Àü½Å¿¡ »ê¼Ò¸¦ ÈíÀÔ½ÃŲ´Ù. °í¾Ð½ÇÀº Å©°í ÀÛÀº ¿©·¯ °¡Áö°¡ ÀÖÀ¸¸ç, ±¸Á¶»ó 1½Ç½Ä-2½Ç½Ä-´Ù½Ç½ÄÀÌ ÀÖ´Ù. °¡¾Ð °¡½ºÀÇ Á¾·ù¿¡´Â »ê¼Ò-°ø±â-È¥ÇÕ °¡½ºµîÀÌ ÀÖ°í, 2~3 ´ë±â¾Ð ¶Ç´Â ±× ÀÌ»óÀÇ °í¾Ð ȯ°æÀ» ¸¸µç´Ù. ÀÓ»óÀûÀ¸·Î ÀÀ¿ë¹üÀ§°¡ ³Ð¾î¼ ±â°èÀû È¿°ú¿¡ ÀÇÇÏ¿© Àá¼öºÎº´À̳ª âÀÚ°ü¸¶ºñ¿¡ ÀÇÇÑ Ã¢ÀÚÆó»ö Ä¡·á µî¿¡ À¯È¿Çϰí, °¡½º±ËÀú µîÀÇ ¹«»ê¼Ò¼º ¼¼±Õ°¨¿°¿¡¼µµ ÀÌ¿ëµÈ´Ù. ¶Ç »ê¼Ò¿î¹ÝÈ¿°ú¿¡ ÀÇÇÏ¿© ÀÏ»êÈź¼Ò-½É±Ù°æ»ö-³ú»öÀüÁõ-ÃâÇ÷¼îÅ©¿¡ ÀÇÇÑ ±Þ¼ºÀÇ Á¶Á÷»ê¼Ò°áÇÌÀÇ Ä¡·á¿¡ À¯È¿ÇÏ´Ù. ¶Ç ¾ÏÀÇ ¹æ»ç¼±¿ä¹ý¿¡ º´¿ëÇϸé ÀÌ ¿ä¹ýÀ¸·Î ¾Ï¼¼Æ÷ÀÇ ºÐ¿ÀÌ ¿Õ¼ºÇØÁ®, ¼¼Æ÷ºÐ¿ ÁßÀÎ ¼¼Æ÷¿¡ ¹æ»ç¼±À» Á¶»çÇÔÀ¸·Î½á ºÐ¿´É·ÂÀ» ¾ø¾Ö´Â µ¥ À¯È¿ÇÏ¿© °í¾Ð»ê¼ÒÈíÀÔÁ¶»ç¹ýÀ̶ó°í ÇÑ´Ù. |
||
| ¿µ¹® | interstitial therapy | ÇÑ±Û | ±ÙÁ¢Ä¡·á |
|---|---|---|---|
| ¼³¸í | ÁÖ·Î Á¾¾çÀÇ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÏ¿© ÀÎü Á¶Á÷³»¿¡ ¹æ»ç¼± ¹°ÁúÀ» »ðÀÔÇÏ¿© ¹æ»ç¼±À» Á¶»çÇÏ´Â Ä¡·á¹ýÀÌ´Ù. Brachytherapy¶ó°íµµ ÇÑ´Ù. |
||
| ¿µ¹® | symptomatic therapy | ÇÑ±Û | ´ëÁõ¿ä¹ý |
|---|---|---|---|
| ¼³¸í | º´ÀÇ ¿øÀÎÀ» ã¾Æ ¾ø¾Ö±â °ï¶õÇÑ »óȲ¿¡¼, °ÑÀ¸·Î ³ªÅ¸³ º´ÀÇ Áõ»ó¿¡ ´ëÀÀÇÏ¿© óġ¸¦ ÇÏ´Â Ä¡·á¹ý. ¿ÀÌ ³ôÀ» ¶§¿¡ ¾óÀ½ÁָӴϸ¦ ´ë°Å³ª ÇØ¿Á¦¸¦ ½á¼ ¿À» ³»¸®°Ô ÇÏ´Â µûÀ§°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. |
||
| ¿µ¹® | radiation therapy | ÇÑ±Û | ¹æ»ç¼±¿ä¹ý |
|---|---|---|---|
| ¼³¸í | X¼±, ¥ã¼±ÀÇ ÀüÀÚ¹æ»ç¼±À̳ª ÀüÀÚ¼±, ¾çÀÚ¼±, Áß¼ºÀÚ¼± µîÀÇ ÀÔÀÚ¹æ»ç¼±À» ÀÌ¿ëÇØ, ÁÖ·Î ¾Ç¼º Á¾¾ç Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â Ä¡·á¹ýÀÌ´Ù. ¾Ï¼¼Æ÷°¡ ÁÖÀ§ÀÇ Á¤»ó¼¼Æ÷º¸´Ùµµ ¹æ»ç¼± °¨¼ö¼ºÀÌ ³ôÀº Á¡À» ÀÌ¿ëÇÏ¿©, Á¤»ó¼¼Æ÷ÀÇ ¼Õ»óÀ» °¡´ÉÇÑ ÇÑ ÃÖ¼Ò·Î ¾ïÁ¦ÇÏ¸é¼ ¾Ï¼¼Æ÷¸¦ ÆÄ±«ÇÑ´Ù. »ç¿ëµÇ´Â ¹æ»ç¼±¿¡´Â ¹ÐºÀ¼Ò¼±¿ø¿¡¼ ³ª¿À´Â ¥ã¼±, Á÷¼±°¡¼Ó±â¿¡¼ ¾ò¾îÁö´Â °í¿¡³ÊÁö X¼±°ú ÀüÀÚ¼±, ÅÚ·¹ÄÚ¹ßÆ®ÀåÄ¡¿¡ ÀÇÇÑ 60CoÀÇ ¥ã¼±°ú, º£Å¸Æ®·Ð¿¡ ÀÇÇÑ ÀüÀÚ¼±, »çÀÌÅ©·ÎÆ®·Ð¿¡¼ ¾ò¾îÁö´Â ¾çÀÚ¼±, Áß¼ºÀÚ¼± µîÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | radiation therapy | ÇÑ±Û | ¹æ»ç¼±Ä¡·á |
|---|---|---|---|
| ¼³¸í | ¹æ»ç¼±ÀÇ »ì±ÕÈ¿°ú³ª ¼¼Æ÷¸¦ Á×ÀÌ´Â È¿°ú¸¦ Ä¡·á¿¡ ÀÌ¿ëÇÏ´Â ¹æ¹ýÀ¸·Î, Á¼Àº Àǹ̷Π¾ÏÀÇ ¹æ»ç¼±Ä¡·á¸¦ ÀǹÌÇÑ´Ù. ¾Ï¿¡ ´ëÇÑ ¹æ»ç¼±Ä¡·á´Â ¾Ï¼¼Æ÷¸¦ Á×À̴µ¥ È¿°ú°¡ Å« º£Å¸¼±À» ÁÖ·Î »ç¿ëÇÑ´Ù. ÇÏÁö¸¸, ÀÌ·± ¹æ»ç¼±Ä¡·á´Â Á¤»ó¼¼Æ÷¿¡µµ Å« ¿µÇâÀ» ³¢ÃÄ ÀÌ¿¡ µû¸¥ ±â´ÉÀÇ Àå¾Ö¸¦ °¡Á®¿Ã ¼ö ÀÖ´Ù. µû¶ó¼ ¹æ»ç¼±Ä¡·á¿¡ À־ ´ÜÁö ±× ¾Ï¼¼Æ÷¿¡ ´ëÇÑ ÀÛ¿ë»Ó¸¸ ¾Æ´Ï¶ó, Á¤»ó¼¼Æ÷¿¡ ´ëÇÑ ÀÛ¿ëµµ °í·ÁÇÏ¿© ½ÃÇàÇÑ´Ù. |
||
| IST | inappropriate sinus tachycardia; insulin sensitivity test; insulin shock therapy; International Soci... |
|---|---|
| GT | gait training; galactosyl transferase; gastrostomy; generation time; genetic therapy; gingiva treatm... |
| RT | radiologic technologist; radiotelemetry; radiotherapy; radium therapy; rapid tranquilization; reacti... |
| GCS | Glasgow Coma Scale |
| EMV | eye, motor, voice [Glasgow coma scale] |
| diabetic coma | A severe metabolic derangement that occurs in the absence of insulin. Insulin allows the body to absorb glucose into cells for energy production. In the absence of insulin, the body starts to break down fats for fuel. A metabolic byproduct of fat metabolism is referred to as a ketone. The presence of elevated blood ketones in this setting is known as diabetic ketoacidosis. In extreme, untreated cases, this can lead to coma and death. (27 Sep 1997) |
|---|---|
| thyrotoxic coma | Coma preceding death in severe hyperthyroidism, as in thyroid storm or thyrotoxic crisis. (05 Mar 2000) |
| trance coma | The deep sleep following major hypnosis. Synonym: trance coma. (05 Mar 2000) |
| uraemic coma | A metabolic encephalopathy caused by renal failure. (05 Mar 2000) |
| Kussmaul's coma | A severe metabolic derangement that occurs in the absence of insulin. Insulin allows the body to absorb glucose into cells for energy production. In the absence of insulin, the body starts to break down fats for fuel. A metabolic byproduct of fat metabolism is referred to as a ketone. The presence of elevated blood ketones in this setting is known as diabetic ketoacidosis. In extreme, untreated cases, this can lead to coma and death. (27 Sep 1997) |
| amorphous insulin zinc suspension | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
| anti-insulin | A factor, usually an antibody, which antagonises the action of insulin. (05 Mar 2000) |
| anti-insulin antibody | A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result. (27 Sep 1997) |
| biphasic insulin | <protein> A type of insulin that is a mixture of intermediate- and fast-acting insulin. (09 Oct 1997) |
| receptors, insulin | Cell surface proteins that bind insulin and trigger intracellular changes which influence the behaviour of cells. The best understood physiological consequence of insulin receptor activation is increased transport of glucose into most cells, which controls the rate of carbohydrate metabolism. The insulin receptor is a multifunctional protein complex that has intrinsic tyrosine kinase activity and is capable of autophosphorylation. (12 Dec 1998) |
| receptors, insulin-like-growth factor I | Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity. (12 Dec 1998) |
| receptors, insulin-like-growth-factor II | Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity. (12 Dec 1998) |
| regular insulin | A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours. Synonym: globin insulin. (05 Mar 2000) |
| regular insulin injection | A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma. Synonym: regular insulin injection. (05 Mar 2000) |
| globin insulin | A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours. Synonym: globin insulin. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|